Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MK-3475A |
Synonyms | |
Therapy Description |
Limited information is currently available on MK-3475A, a putative formulation of Keytruda (pembrolizumab) with MK-5180 (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-3475A | MK 3475A|MK3475A | Limited information is currently available on MK-3475A, a putative formulation of Keytruda (pembrolizumab) with MK-5180 (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06099782 | Phase II | MK-3475A Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Recruiting | USA | NZL | FRA | AUS | 6 |